Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Lithuania

- PMLiVE

Pfizer’s antibiotic combination receives EC approval to treat multidrug-resistant infections

Antimicrobial resistance has been declared by WHO as one of the top ten threats to global health

- PMLiVE

UCB’s Bimzelx granted EC approval to treat hidradenitis suppurativa in adults

The regulator’s decision marks Bimzelx’s fourth approved indication within the EU

EU flag

European Parliament approves pharma reform compromise for equal access to new medicines

The new proposal will be finalised after the EU elections take place in June 2024

- PMLiVE

Bristol Myers Squibb’s Reblozyl receives EC approval in myelodysplastic syndromes

The treatment is already approved in the EU to treat anaemia in adults with beta-thalassaemia

- PMLiVE

NHS rolls out artificial pancreas for adults and children with type 1 diabetes in England

Type 1 diabetes accounts for approximately 10% of all diabetes cases in the UK

- PMLiVE

Researchers identify early treatment strategy for diabetic patients at risk of kidney disease

The chronic disease is currently the leading cause of kidney failure in the UK

- PMLiVE

Merck’s Keytruda regimen granted EC approval for expanded lung cancer use

The approval represents the sixth lung cancer indication for the anti-PD-1 therapy in Europe

- PMLiVE

Bristol Myers Squibb announces EC approval for multiple myeloma therapy Abecma

Approximately 50,000 cases of the blood cancer are diagnosed in Europe every year

- PMLiVE

Pfizer’s 20-valent pneumococcal vaccine receives EC approval for infants and children

The 20 serotypes included in Prevenar 20 cause the majority of circulating pneumococcal disease

- PMLiVE

Pfizer’s Velsipity granted EC approval for ulcerative colitis in patients aged from 16 years

The immune-mediated inflammatory bowel disease affects approximately 2.6 million people in Europe

- PMLiVE

PrecisionLife and Metrodora Institute partner for diagnosis and treatment of chronic diseases

The collaboration will first focus on developing products for long COVID and ME/CFS

Biogen Idec building

Biogen receives EC approval for Skyclarys in Friedreich’s ataxia patients

The company gained access to the drug through its $7.3bn acquisition of Reata Pharmaceuticals

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links